We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.03%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.01B
AUM Growth
-$490M
Cap. Flow
-$415M
Cap. Flow %
-40.98%
Top 10 Hldgs %
28.64%
Holding
97
New
5
Increased
11
Reduced
69
Closed
8

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18M
2
BNTX icon
BioNTech
BNTX
+$14.3M
3
ALGN icon
Align Technology
ALGN
+$7.3M
4
GDRX icon
GoodRx Holdings
GDRX
+$5.39M
5
CYTK icon
Cytokinetics
CYTK
+$5.15M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$29.9M
2
PFE icon
Pfizer
PFE
+$24.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$23.8M
4
ELV icon
Elevance Health
ELV
+$23.7M
5
MCK icon
McKesson
MCK
+$22.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Industrials 1.09%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
76
Phathom Pharmaceuticals
PHAT
$688M
$3.2M 0.32%
235,210
+49,000
+26% +$792K
BIIB icon
77
Biogen
BIIB
$30.1B
$3.16M 0.31%
15,000
-100,000
-87% -$21.7M
PHR icon
78
Phreesia
PHR
$758M
$3.08M 0.3%
117,000
-6,465
-5% -$198K
STXS icon
79
Stereotaxis
STXS
$145M
$2.97M 0.29%
797,330
-2,670
-0.3% -$12.6K
VRAY
80
DELISTED
ViewRay, Inc.
VRAY
$2.88M 0.28%
735,000
-40,000
-5% -$170K
IONS icon
81
Ionis Pharmaceuticals
IONS
$9.21B
$2.63M 0.26%
71,000
-4,000
-5% -$131K
EPIX
82
DELISTED
ESSA Pharma
EPIX
$2.54M 0.25%
410,923
-9,077
-2% -$79.8K
MGNX icon
83
MacroGenics
MGNX
$249M
$2.53M 0.25%
287,081
-13,572
-5% -$150K
OLK
84
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$2.47M 0.24%
140,000
– –
GTHX
85
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.4M 0.24%
316,137
-8,863
-3% -$84K
OLMA icon
86
Olema Pharmaceuticals
OLMA
$911M
$2.13M 0.21%
500,000
– –
RPID icon
87
Rapid Micro Biosystems
RPID
$84.8M
$2.04M 0.2%
300,000
+103,913
+53% +$765K
PVLA
88
Palvella Therapeutics
PVLA
$2.22B
$909K 0.09%
3,750
– –
ANNX icon
89
Annexon
ANNX
$875M
$683K 0.07%
250,000
– –
KYNB
90
Kyntra Bio
KYNB
$28.6M
– –
-8,000
Closed -$2.82M
HCA icon
91
HCA Healthcare
HCA
$89.1B
– –
-59,000
Closed -$15.2M
INNV icon
92
InnovAge Holding
INNV
$1.39B
– –
-150,000
Closed -$741K
SAGE
93
DELISTED
Sage Therapeutics
SAGE
– –
-115,000
Closed -$4.97M
ZBH icon
94
Zimmer Biomet
ZBH
$18.5B
– –
-92,700
Closed -$11.5M
DCPH
95
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-60,000
Closed -$604K
EPZM
96
DELISTED
Epizyme, Inc
EPZM
– –
-265,000
Closed -$702K
VCRA
97
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-60,000
Closed -$3.84M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rhenman & Partners Asset Management held 97 positions worth $1.01B, down 33% from $1.5B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $415M in Q1 2022, closing 8 positions and reducing 69 holdings. Its most notable exit was HCA Healthcare, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Regeneron Pharmaceuticals worth $19.9M.

  • Rhenman & Partners Asset Management's largest Q1 2022 buy was Regeneron Pharmaceuticals: 28,500 shares worth $19.9M.
  • Rhenman & Partners Asset Management added most to Align Technology in Q1 2022, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2022 reduction was UnitedHealth, cutting an estimated $29.9M.
  • Rhenman & Partners Asset Management fully exited HCA Healthcare in Q1 2022, selling an estimated $15.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.01B portfolio in Q1 2022.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 8 in Q1 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 33% quarter-over-quarter to $1.01B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2022, filed 13 May 2022.